{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:53:23Z","timestamp":1788314003489,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of Guangxi Province","award":["2023GXNSFAA026126"],"award-info":[{"award-number":["2023GXNSFAA026126"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed\/refractory acute leukemia (R\/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R\/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient therapies. CD38 expression has been observed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Daratumumab is a humanized anti-CD38 monoclonal antibody used to treat multiple myeloma and has been reported to treat R\/R-AL safely and effectively. The clinical data of 10 adult patients with R\/R-AL who were treated with a daratumumab-based salvage regimen between July 2018 and May 2023 at our center were analyzed retrospectively. Seven AML and three ALL cases were included in the analysis. Seven (70%) patients showed responses to the treatments (complete response [CR], 60%; partial response [PR], 10%). Of the seven responders, three underwent allogenic stem cell transplantation (ASCT), including one who underwent a second ASCT. Among the five patients with R\/R AML who had prior exposure to venetoclax, three achieved a therapeutic response (two CR and one PR) when re-treated with venetoclax in combination with daratumumab. The median follow-up time was 6.15 months (0.9\u201321 months). Overall survival and event-free survival rates at 12 months were 68.6% and 40.0%, respectively. The main adverse events included grade 3 febrile neutropenia (20%) and grade 3 hematological toxicities (60%). The daratumumab-based salvage regimen offers patients with R\/R-AL the opportunity of remission with acceptable tolerability, creating the possibility of bridging ASCT.<\/jats:p>","DOI":"10.1007\/s00277-024-05892-9","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:02:37Z","timestamp":1721797357000},"page":"4057-4063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience"],"prefix":"10.1007","volume":"103","author":[{"given":"Yi","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2182-029X","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"7","key":"5892_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","volume":"121","author":"SJ Forman","year":"2013","unstructured":"Forman SJ, Rowe JM (2013) The myth of the second remission of acute leukemia in the adult. Blood 121(7):1077\u20131082. https:\/\/doi.org\/10.1182\/blood-2012-08-234492","journal-title":"Blood"},{"issue":"9","key":"5892_CR2","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23(9):1969\u20131978. https:\/\/doi.org\/10.1200\/JCO.2005.06.027","journal-title":"J Clin Oncol"},{"issue":"8","key":"5892_CR3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD et al (2018) Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol 93(8):1074\u20131081. https:\/\/doi.org\/10.1002\/ajh.25162","journal-title":"Am J Hematol"},{"issue":"1","key":"5892_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW Van De Donk","year":"2016","unstructured":"Van De Donk NW, Janmaat ML, Mutis T et al (2016) Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 270(1):95\u2013112. https:\/\/doi.org\/10.1111\/imr.12389","journal-title":"Immunol Rev"},{"issue":"6","key":"5892_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","volume":"127","author":"NW Van De Donk","year":"2016","unstructured":"Van De Donk NW, Moreau P, Plesner T et al (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127(6):681\u2013695. https:\/\/doi.org\/10.1182\/blood-2015-10-646810","journal-title":"Blood"},{"issue":"3","key":"5892_CR6","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, Themeli M, De Jong-Korlaar R et al (2019) CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 104(3):e100\u2013e103. https:\/\/doi.org\/10.3324\/haematol.2018.192757","journal-title":"Haematologica"},{"key":"5892_CR7","doi-asserted-by":"publisher","first-page":"106332","DOI":"10.1016\/j.leukres.2020.106332","volume":"91","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xue S, Liu F, Wang J (2020) Daratumumab for quick and sustained remission in post-transplant relapsed\/refractory acute lymphoblastic leukemia. Leuk Res 91:106332. https:\/\/doi.org\/10.1016\/j.leukres.2020.106332","journal-title":"Leuk Res"},{"issue":"2","key":"5892_CR8","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/bjh.16154","volume":"187","author":"S Mirgh","year":"2019","unstructured":"Mirgh S, Ahmed R, Agrawal N et al (2019) Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol 187(2):e33\u2013e35. https:\/\/doi.org\/10.1111\/bjh.16154","journal-title":"Br J Haematol"},{"issue":"3","key":"5892_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-023-05083-y","volume":"102","author":"M Stanulla","year":"2023","unstructured":"Stanulla M, Schewe DM, Bornhauser B et al (2023) Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia. Ann Hematol 102(3):669\u2013672. https:\/\/doi.org\/10.1007\/s00277-023-05083-y","journal-title":"Ann Hematol"},{"issue":"6","key":"5892_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/2040620717703012","volume":"8","author":"V Sedov","year":"2017","unstructured":"Sedov V, Stuart RK (2017) Vosaroxin in relapsed\/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol 8(6):185\u2013195. https:\/\/doi.org\/10.1177\/2040620717703012","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"5892_CR11","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109(3):944\u2013950. https:\/\/doi.org\/10.1182\/blood-2006-05-018192","journal-title":"Blood"},{"issue":"9","key":"5892_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","volume":"23","author":"KJ Norsworthy","year":"2018","unstructured":"Norsworthy KJ, Ko CW, Lee JE et al (2018) FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist 23(9):1103\u20131108. https:\/\/doi.org\/10.1634\/theoncologist.2017-0604","journal-title":"Oncologist"},{"issue":"12","key":"5892_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1096\/fasebj.10.12.8903511","volume":"10","author":"K Mehta","year":"1996","unstructured":"Mehta K, Shahid U, Malavasi F (1996) Human CD38, a cell-surface protein with multiple functions. FASEB J 10(12):1408\u20131417. https:\/\/doi.org\/10.1096\/fasebj.10.12.8903511","journal-title":"FASEB J"},{"issue":"1","key":"5892_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0145-2126(00)00093-x","volume":"25","author":"S Deaglio","year":"2001","unstructured":"Deaglio S, Mehta K, Malavasi F (2001) Human CD38: A (r)evolutionary story of enzymes and receptors. Leuk Res 25(1):1\u201312. https:\/\/doi.org\/10.1016\/s0145-2126(00)00093-x","journal-title":"Leuk Res"},{"issue":"9","key":"5892_CR15","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.4049\/jimmunol.161.9.4702","volume":"161","author":"M Konopleva","year":"1998","unstructured":"Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K (1998) Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol 161(9):4702\u20134708. https:\/\/doi.org\/10.4049\/jimmunol.161.9.4702","journal-title":"J Immunol"},{"key":"5892_CR16","doi-asserted-by":"publisher","first-page":"1007783","DOI":"10.3389\/fonc.2022.1007783","volume":"12","author":"X Zhong","year":"2022","unstructured":"Zhong X, Ma H (2022) Targeting CD38 for acute leukemia. Front Oncol 12:1007783. https:\/\/doi.org\/10.3389\/fonc.2022.1007783","journal-title":"Front Oncol"},{"issue":"2","key":"5892_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2019.242974","volume":"106","author":"JJ Mistry","year":"2021","unstructured":"Mistry JJ, Moore JA, Kumar P et al (2021) Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells. Haematologica 106(2):589\u2013592. https:\/\/doi.org\/10.3324\/haematol.2019.242974","journal-title":"Haematologica"},{"issue":"4","key":"5892_CR18","doi-asserted-by":"publisher","first-page":"e7627","DOI":"10.7759\/cureus.7627","volume":"12","author":"B Pati\u00f1o-Escobar","year":"2020","unstructured":"Pati\u00f1o-Escobar B, Ramos R, Linares M, Mej\u00eda A, Alcal\u00e1 S (2020) CD38: from positive to negative expression after daratumumab treatment. Cureus 12(4):e7627. https:\/\/doi.org\/10.7759\/cureus.7627","journal-title":"Cureus"},{"issue":"4","key":"5892_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2021.279851","volume":"107","author":"M Cerrano","year":"2022","unstructured":"Cerrano M, Bonifacio M, Olivi M et al (2022) Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational campus ALL study. Haematologica 107(4):996\u2013999. https:\/\/doi.org\/10.3324\/haematol.2021.279851","journal-title":"Haematologica"},{"issue":"10","key":"5892_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J et al (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032\u20132041. https:\/\/doi.org\/10.1182\/blood-2011-12-399287","journal-title":"Blood"},{"issue":"11","key":"5892_CR21","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F et al (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186\u20133191. https:\/\/doi.org\/10.1002\/cncr.23919","journal-title":"Cancer"},{"issue":"9","key":"5892_CR22","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21(9):1907\u20131914. https:\/\/doi.org\/10.1038\/sj.leu.2404824","journal-title":"Leukemia"},{"issue":"4","key":"5892_CR23","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1111\/bjh.18595","volume":"200","author":"L Goursaud","year":"2023","unstructured":"Goursaud L, Berthon C, Quesnel B (2023) Successful bridging to cell therapy for relapsed\/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase. Br J Haematol 200(4):e37\u2013e39. https:\/\/doi.org\/10.1111\/bjh.18595","journal-title":"Br J Haematol"},{"issue":"6","key":"5892_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E et al (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1465","journal-title":"Cancer Discov"},{"issue":"1","key":"5892_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson A, Trabal A, Mccall D et al (2021) Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers 14(1):150. https:\/\/doi.org\/10.3390\/cancers14010150","journal-title":"Cancers"},{"issue":"1","key":"5892_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bjh.15077","volume":"181","author":"A Rashidi","year":"2018","unstructured":"Rashidi A, Weisdorf DJ, Bejanyan N (2018) Treatment of relapsed\/refractory acute myeloid leukaemia in adults. Br J Haematol 181(1):27\u201337. https:\/\/doi.org\/10.1111\/bjh.15077","journal-title":"Br J Haematol"},{"issue":"1","key":"5892_CR27","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.16960","volume":"191","author":"M Cerrano","year":"2020","unstructured":"Cerrano M, Castella B, Lia G et al (2020) Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. Br J Haematol 191(1):e28\u2013e32. https:\/\/doi.org\/10.1111\/bjh.16960","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05892-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:05:32Z","timestamp":1729933532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05892-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5892"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05892-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the Institutional Review Committee of the Ethics Committee of Guangxi Medical University (Approval No: 2024-E299-01), and all investigations were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need to obtain informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}